// App-Quantinova.ai

4086 : Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma.

Researchers

Presenter

  • Lynn G. Feun

Principal Investigators

  • Ying-Ying Li

  • Medhi Wangpaichitr

  • Patricia Denise Jones

  • Stephen P. Richman

  • Beatrice Madrazo

  • Deukwoo Kwon

  • Paul Martin

  • Peter Joel Hosein

  • Niramol Savaraj

Medical Centers

  • Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL

  • University of Miami, Miami, FL

  • VA Medical Center, Miami, FL

  • University of Miami/Sylvester Cancer Center, Miami, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Pembrolizumab

  • Sorafenib

Outcome

  • N/A

Study Design

  • Fixed Dose

Phase

  • II

Study Id's

  • NCT02658019

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved